We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 18, 2022

Long-Term Outcomes of Abiraterone Acetate Plus Prednisone in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer

ESMO Open

 

Additional Info

ESMO Open
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study
ESMO Open 2022 Apr 01;7(2)100431, G Procopio, VE Chiuri, M Giordano, AR Alitto, R Maisano, R Bordonaro, S Cinieri, S Rossetti, S De Placido, M Airoldi, L Galli, D Gasparro, GM Ludovico, PF Guglielmini, C Carella, P Nova, M Aglietta, L Schips, P Beccaglia, A Sciarra, L Livi, D Santini

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading